NEW YORK (GenomeWeb News) – Response Genetics today reported a 32 percent drop year over year in its first-quarter revenues.

For the period ended March 31, the Los Angeles-based molecular diagnostics firm recorded $4 million in revenues, down from $5.9 million a year ago. The company attributed the drop to a decrease in its pharmaceutical-related business, while revenues from its Response DX genetic tests dropped to $3 million from $3.1 million.

Its net loss for the period spiked to $3.1 million, or $.14 per share, from $256,891, or $.01 per share, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.